Akero Therapeutics

Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology response Data contribute to growing body of support around the anti-fibrotic activity of EFX in patients with pre-cirrhotic MASH. 10 May 2025 -- California, US -- Akero Therapeutics, Inc, a clinical-stage company developing transformational treatments for patients with serious metabolic...

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine

Results support potential benefit of efruxifermin (EFX) to elicit fibrosis improvement in patients with compensated cirrhosis (F4 fibrosis) due to MASH 96-week data from SYMMETRY trial presented at EASL Congress 2025 9 May 2025 -- California, US -- Akero Therapeutics, Inc, a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high...
601 Gateway Boulevard, Suite 350 South San Francisco, CA 94080 (650) 487-6488